23/04/2026 Cumberland Pharmaceuticals announced strategic transaction to integrate commercial business with Apotex Cumberland Pharmaceuticals announced strategic transaction to integrate commercial business with Apotex (Ref) Cumberland Pharmaceuticals announced it had entered into an agreement with an affiliate of Apotex to integrate their branded US business. Under the terms of the agreement, Apotex was to acquire Cumberland's line of branded pharmaceuticals for cash conside

31/03/2026 Galapagos and Gilead entered into a binding agreement to collaborate on advancing a T cell engager program for autoimmune diseases Galapagos and Gilead entered into a binding agreement to collaborate on advancing a T cell engager program for autoimmune diseases ( Ref ) Galapagos and Gilead Sciences entered into a binding collaboration agreement to co-develop gamgertamig (OM336; BCMAxCD3 T cell engager) originally developed by Ouro Medicines targeting deep B-cell de

10/03/2026 Redx’s RXC008 granted US FDA fast track designation for fibrostenotic CD Redx’s RXC008 granted US FDA fast track designation for fibrostenotic CD ( Ref ) Redx Pharma announced that the US FDA had granted fast track designation to RXC008 (a GI-restricted pan-ROCK inhibitor) for the treatment of patients with fibrostenotic crohn’s disease (CD) Lisa Anson, CEO, Redx Pharma: “ Redx have been working closely with the FDA and the STAR consortium to define the regulatory

09/03/2026 Pfizer announced Phase 2 results of tilrekimig in AD Vertex announced Phase 3 results of Povetacicept in IgA Nephropathy Pfizer announced Phase 2 results of tilrekimig in AD ( Ref ) Pfizer announced positive topline results from its Phase 2 study that evaluated tilrekimig (PF-07275315; trispecific antibody targets Il-4, IL-13 and TSLP) for the treatment of adult patients with moderate to severe atopic dermatitis (AD) The study met its primary endpoint, demonstratin